Long-Acting Injectable antipsychotics (LAI) is one of the trusted ways, according to the research, to reduce the hospitalization risk. It is used for schizophrenia patients, who relapse and do not show any response to antipsychotic medications.
The findings of the research, led by John M. Kane, MD, Departments of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, are found in the journal of JAMA Psychiatry.
Study for Early Phase of Schizophrenia
The study shows a comparison between the effect of long-acting injectable antipsychotics and the care given at the first hospitalization during the early phase of schizophrenia.
Several people with schizophrenia show frequent recidivism and hospitalization throughout their life. One factor of this cause is the lack of response to medications. As per the recent findings, long-acting injectable may have the potency to increase the compliance of medications.
The team planned a trial to observe the prevention in the relapse of schizophrenia. With cluster randomization, the team followed a two-year record of 489 patents in 39 medical centers in the 19 US states.
The research program began in December 2014 and ended in March 2019. The participants had at least an average age of 25. Within the two-year period, only 225 people had a year or even less of lifetime antipsychotic use.
They planned for site randomization. Nineteen of the clinics went for treatment with long-acting aripiprazole monohydrates once monthly, depending on the condition (AOM). Meanwhile, the other twenty clinics went for their usual treatment as per the clinician’s choice condition (CC).
The study had patients who had schizophrenia diagnosis confirmed with a structured clinical interview. They were all between 18 and 35 and had a record of five or fewer years of antipsychotic use.
Researchers did not go for restrictions either at clinician choice condition sites or AOM (long-acting injectable sites), except the use of aripiprazole monohydrates at AOM. However, the prescription must be according to the guidelines from the US Food and Drug Administration.
They maintain a track by having participant interviews every two months and service use resource form at every four months. Moreover, the findings were confirmed through medical records and visits.
Analysis of the Findings
As per the analysis, 52 from AOM and 91 from CC paid at least one hospital visit. Until the first hospitalization, the average survival rate for AOM participants was 613.7 days (95% CI, 582.3-645.1 days) and 530.6 days (95% CI, 497.3-563.9 days) for the other one – CC participants.
For the first time hospitalization for schizophrenia, the risk was only 0.56 (95% CI, 0.34- 0.92; P = .02), which means it showed a positive response for aripiprazole once a month.
In contrast, 0.73 (95% CI, 0.65-0.83) was for AOM patients and 0.58 (95% CI, 0.50-0.67) for the CC patients. The number of patients needing treatment went to seven when comparing long-acting aripiprazole monohydrate with standard care.
The authors highlight how long-acting injectable antipsychotics are economically and physically important to reduce the hospitalization risk in the early phase of schizophrenia. Clinicians should now broadly consider using this treatment.
Investigators found the polygenic scores (PGS) of schizophrenia patients that could have an effect on cognitive development. A research team of Dwight Dickinson, Ph.D., National Institute of Mental Health, examined whether different cognitive development could influence variations against the dimensions of genetics.
With analysis, they found three subgroups: preadolescent cognitive impairment by 19%, adolescent disruption of cognitive development by 44%, and cognitively stable adolescent development by 37%.